Table 2.
Factors associated with virologic non‐suppression and loss to follow up at 24 months on ART among adolescents who initiate ART at the ages of 15–19 years
| Virologic non‐suppression | Loss to follow up | |||
|---|---|---|---|---|
| Patient characteristics | Adjusted sub‐distribution hazard ratios (aSHRs) a | 95% confidence interval | Adjusted sub‐distribution hazard ratios (aSHRs) a | 95% confidence interval |
| Sex b | ||||
| Male | 1 | 1 | ||
| Female (non‐pregnant) | 1.14 | 0.88, 1.46 | 0.97 | 0.82, 1.14 |
| Female (pregnant) | 1.21 | 0.85, 1.72 | 1.00 | 0.82, 1.22 |
| Age, years, at ART initiation | ||||
| 15 | 1 | 1 | ||
| 16 | 0.70 | 0.50, 0.99 | 1.17 | 0.92, 1.48 |
| 17 | 0.57 | 0.40, 0.81 | 1.19 | 0.94, 1.50 |
| 18 | 0.62 | 0.45, 0.86 | 1.28 | 1.03, 1.59 |
| 19 | 0.50 | 0.36, 0.68 | 1.24 | 1.01, 1.53 |
| WHO Stage at ART initiation | ||||
| 1&2 | 1 | 1 | ||
| 3&4 | 1.29 | 0.98, 1.68 | 0.91 | 0.79, 1.06 |
| CD4 count (cells/μl) at ART initiation | ||||
| ≤200 | 1 | 1 | ||
| 201–350 | 0.56 | 0.44, 0.71 | 1.31 | 1.10, 1.56 |
| 351–500 | 0.41 | 0.31, 0.55 | 1.43 | 1.19, 1.72 |
| >500 | 0.22 | 0.16, 0.31 | 1.35 | 1.13, 1.62 |
| Year of ART initiation | ||||
| 2004–2006 | 1 | 1 | ||
| 2007–2009 | 0.86 | 0.54, 1.39 | 1.41 | 1.00, 1.99 |
| 2010–2012 | 1.20 | 0.77, 1.88 | 1.40 | 1.01, 1.95 |
| 2013–2015 | 1.08 | 0.69, 1.70 | 1.84 | 1.32, 2.56 |
| 2016–2019 | 1.22 | 0.74, 1.98 | 2.55 | 1.81, 3.57 |
a
Adjusted for health facility where the patients initiated ART.
b
Sex of adolescents refers to the field in the individual patient health record/file.
Bold figures represent effect estimates that were significant at the 5%. level of significance.